MORRISVILLE, N.C.--(BUSINESS WIRE)--
Oxygen Biotherapeutics, Inc. (“OBI”) (OXBT), today announced Col. (ret.) Charles L. Pamplin III, M.D., was appointed to the position of Chief Medical Officer effective May 20. In this position, he reports to the Chief Executive Officer. Dr. Pamplin will be implementing the Company’s strategic clinical development plan. His responsibilities will include overseeing Clinical Development of Oxycyte, OBI’s lead product candidate currently in Phase IIb clinical trials in Israel and Switzerland for traumatic brain injury, as well as preclinical studies here in the U.S.
“At this stage, the board felt it is was important to elevate the medical and product development expertise of the company as we push through our Phase IIb clinical trials and gather the data necessary to answer the FDA questions regarding Oxycyte,” said Michael Jebsen, Interim CEO and Chief Financial Officer. “We believe Dr. Pamplin’s expertise in drug development, the drug approval process, investor outreach, and strategy, as well as his military ties will prove highly beneficial to the company immediately, and over the long term.”
Most recently, Dr. Pamplin has been serving as president of Medicines Oracle, a medical consultancy to the pharmaceutical industry. Prior to that, he was Vice President of Clinical Development at King Pharmaceuticals, Inc., which has been acquired by Pfizer Inc. From May 2000 to March 2007 he was Vice President, Medical Affairs, at King. At King he contributed to the development of various adenosine receptor agonists, antagonists, and allosteric modifiers. He contributed to the development of Estrasorb™, bremelanotide, Remoxy, Vanquix™, Corvue, and sonodenoson and to the life cycle development of Altace®, Levoxyl®, and Cytomel®. Prior to joining King Pharmaceuticals, he was Vice President of Quintiles Americas Internal Medicine Business Unit. He managed numerous medical specialty programs at Quintiles including women’s health, urology, and dermatology.
Dr. Pamplin is a licensed and board certified physician and a retired U.S. Army Colonel (Medical Corps), specializing in Internal Medicine, Clinical Pharmacology, Business Management, and Medical Informatics. During his 22 year distinguished military career he contributed to the development of anti-malarial, antileishmanial, and chemical defense drugs and devices. He developed prophylactic and therapeutic drug treatments and strategies. In addition, he has received several military awards and honors, including the Legion of Merit, the National Defense Service Medal, and the Army Achievement Medal among others.
After receiving his medical degree from the University of Maryland, he completed his internship and residency in Internal Medicine at Walter Reed Medical Center and his post-graduate training in Clinical Pharmacology at Walter Reed Institute of Research, in Washington, D.C. He is a graduate of the Command and General Staff College. He received his undergraduate degree from Wake Forest University.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte® that is currently in clinical and preclinical studies for intravenous delivery for indications such as traumatic brain injury, decompression sickness and stroke. The company is also developing PFC-based creams and gels for topical delivery to the skin for dermatologic conditions and potentially wound care. In addition, the Company has commercialized its Dermacyte® line of skin care cosmetics for the anti-aging market. Dermacyte is now out-licensed to Valor Cosmetics of Switzerland.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company’s judgment as of the date of this release. The forward-looking statements are subject to a number of risks and uncertainties delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current Form 10-Q filed on March 18, 2013, and our annual report on Form 10-K filed on July 24, 2012, as well as other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Ellen Corliss, 919-855-211
SVP, Investor Relations &